



شبكة المعلومات الجامعية

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

Ain Shams University Information Network
جامعة عين شمس

شبكة المعلومات الجامعية

@ ASUNET



شبكة المعلومات الجامعية
التوثيق الالكتروني والميكروفيلم



شبكة المعلومات الجامعية

جامعة عين شمس

التوثيق الالكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأفلام قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأفلام بعيدا عن الغبار

في درجة حرارة من ١٥-٢٥ مئوية ورطوبة نسبية من ٢٠-٤٠%

To be Kept away from Dust in Dry Cool place of
15-25- c and relative humidity 20-40%

بعض الوثائق

الأصلية تالفة



بالرسالة صفحات نم ترد بالاصل

PYRIMETHAMINE TOXICITY: MODULATING EFFECT OF FOLINIC ACID

*Thesis Submitted For
The Partial Fulfillment Of The Master Degree
"M.Sc" In Forensic Medicine and Toxicology*

By

*Nesrine Abdel Rahman Mahmoud
M.B., B.Ch.*

Under supervision of

**Prof. Dr. Assem Abdel Rehim El
Habashy**

*Professor of Forensic Medicine and Clinical Toxicology
Faculty of Medicine - Ain Shams University*

Prof. Dr. Suzan Moustafa Mahmoud

*Professor of Forensic Medicine and Clinical Toxicology
Faculty of Medicine - Ain Shams University*

Prof. Dr. Adel Gamal El Messery


*Professor of Parasitology and Head of Medical Research Center
Faculty of Medicine - Ain Shams University*

**Faculty of Medicine
Ain Shams University**

2001

د. فؤاد عبدالعال

د. فؤاد عبدالعال
د. فؤاد عبدالعال




بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا عَلَّمْتَنَا
إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ

صَدَقَ اللَّهُ الْعَلِيمُ

البقرة الآية ٣٢



List of Contents

	<i>Page</i>
* <i>List of figures</i>	iii
* <i>List of tables</i>	v
* <i>List of histograms</i>	ix
* <i>List of abbreviations</i>	xii
* <i>Introduction</i>	1
* <i>Aim of the Work</i>	2
* <i>Review Of Literature</i>	
1. <i>Pyrimethamine</i>	
• <i>Historical review</i>	3
• <i>Chemical and physical properties</i>	3
• <i>Pharmacokinetics</i>	4
• <i>Pharmacodynamics</i>	5
• <i>Therapeutic uses</i>	6
• <i>Precautions and contraindications</i>	12
• <i>Drug interactions</i>	13
• <i>Toxicity</i>	13
2. <i>Folic acid</i>	
• <i>Historical review</i>	17
• <i>Chemistry</i>	17
• <i>Physiology</i>	19
• <i>Physical properties</i>	20
• <i>Source and requirements</i>	20
• <i>Pharmacokinetics</i>	21
• <i>Pharmacodynamics</i>	22
• <i>Deficiency</i>	22
3. <i>Folinic acid</i>	
• <i>Chemistry and physical properties</i>	24
• <i>Pharmacokinetics</i>	25
• <i>Pharmacodynamics</i>	27
• <i>Therapeutic uses</i>	28
• <i>Precautions and contraindications</i>	30
• <i>Drug interactions</i>	31
• <i>Toxicity</i>	31

<i>Item</i>	<i>Page</i>
<i>4. Genetics</i>	
• <i>The animal cell</i>	33
• <i>Hereditary materials</i>	34
• <i>Cell cycle</i>	38
- <i>Mitosis</i>	39
- <i>Meiosis</i>	40
• <i>Mutagenesis</i>	
- <i>Definition</i>	42
- <i>Mutagenic agents</i>	42
- <i>Mechanism of actions of mutagens</i>	43
- <i>Types of mutations</i>	43
- <i>DNA repair</i>	47
- <i>Health impact of mutations</i>	49
- <i>Glossary of genetics</i>	
* <i>Methodology</i>	50
* <i>Results</i>	
1. <i>Biochemicals and complete blood picture results</i>	69
2. <i>Chromosomal analysis results</i>	121
* <i>Discussion</i>	171
* <i>Conclusion and recommendations</i>	193
* <i>Summary</i>	195
* <i>References</i>	202
* <i>Arabic summary</i>	

List of Figures

No.	Figure	Chapter	Page
1.	<i>Structural formula of pyrimethamine</i>	3	4
2.	<i>Life cycle of malarial parasites and sites of action of pyrimethamine</i>	3	6
3.	<i>Inhibition of tetrahydrofolate synthesis by sulfonamides and pyrimethamine</i>	3	8
4.	<i>Life cycle of toxoplasma gondii</i>	3	10
5.	<i>The structure and numbering of atoms of folic acid</i>	4	18
6.	<i>The structure formula of pteroyl γ triglutamate</i>	4	18
7.	<i>Bacterial synthesis of folic acid and sites of drug action</i>	4	19
8.	<i>Folate metabolism and intracellular role of folate cofactors</i>	4	22
9.	<i>Structural formula of folinic acid</i>	4	24
10.	<i>Metabolism of leucovorin</i>	4	27
11.	<i>The animal cell structure</i>	5	33
12.	<i>Sugar phosphate backbone and nucleotide pairing of DNA double helix</i>	5	34
13.	<i>Generalized illustration of the DNA molecule showing the individual strands arranged in a double helix configuration</i>	5	35
14.	<i>Diagram showing relation of DNA supercoiling and chromosomes</i>	5	36
15.	<i>Electron micrograph of human chromosomes showing the centromeres and the well defined chromatids</i>	5	37
16.	<i>Stages of cell cycle</i>	5	38
17.	<i>Stages of mitosis</i>	5	39
18.	<i>Stages of meiosis</i>	5	40
19.	<i>Chromosome and chromatid type aberrations</i>	5	46
20.	<i>Excision repair of DNA damage</i>	5	48

No.	Figure	Chapter	Page
21.	<i>Technique of IM injection of rat</i>	6-1	53
22.	<i>Technique of gavage dosing of rat</i>	6-2	53
23.	<i>Technique of IPI injection</i>	6-3	64
24.	<i>A photomicrograph of a metaphase spread of normal albino rat</i>	7-1	165
25.	<i>Photomicrograph of a metaphase spread showing ring chromosome (r).</i>	7-2	165
26.	<i>Photomicrograph of a metaphase spread showing chromatid deletion (d) and fragments (f)</i>	7-3	166
27.	<i>A photomicrograph of two metaphase spread showing chromatid deletion(d) and ring chromosome(r)</i>	7-4	166
28.	<i>A photomicrograph of a metaphase spread showing centromere attenuation of chromosome (A)</i>	7-5	167
29.	<i>A photomicrograph of a metaphase spread showing chromatid gaps(g)</i>	7-6	167
30.	<i>A Photomicrograph of a metaphase spread showing fragments (f).</i>	7-7	168
31.	<i>Photomicrograph of a metaphase spread showing ring chromosome (r).</i>	7-8	168
32.	<i>A photomicrograph of a metaphase spread showing centromere attenuation (A)</i>	7-9	169
33.	<i>A photomicrograph of a metaphase spread showing centromere attenuation (A)</i>	7-10	169
34.	<i>A Photomicrograph of a metaphase spread showing chromatid deletion (d) and chromatid gap (g).</i>	7-11	170
35.	<i>A Photomicrograph of a metaphase spread showing chromatid deletion (d)</i>	7-12	170

List of Tables

No	Table	Chapter	Page
1.	<i>Folate cofactors (Hillman et al; 1996)</i>	4-1	20
2.	<i>Leucovorin calcium preparations. (Covington et al; 1999)</i>	4-2	25
3.	<i>ANOVA one-way statistical analysis and Student "t" test of liver function tests (total bilirubin, ALT, AST, ALP and albumin) in negative control group and pyrimethamine subgroups taken as single oral dose.</i>	7-1	69
4.	<i>ANOVA one-way statistical analysis and student "t" test of complete blood picture in negative control group and pyrimethamine subgroups taken as single oral dose.</i>	7-2	73
5.	<i>ANOVA one way statistical analysis and student "t" test of liver function tests in negative control group and pyrimethamine + folinic acid (2 hours post-treatment) groups where pyrimethamine is taken as a single oral dose (20, 40 and 120 mg/kg) and folinic taken I.M. at a dose of 1 mg/kg.</i>	7-3	78
6.	<i>ANOVA one-way statistical analysis and student "t" test of complete blood picture in negative control group and pyr. + folinic acid (2 hours pretreatment) groups with pyrimethamine taken orally at a single dose of (20, 40 , 120 mg/kg) and folinic taken IM at a dose of 0.1 mg/kg.</i>	7-4	82
7.	<i>ANOVA one-way statistical analysis and student "t" test of liver functions tests in negative control and pyr. + folinic acid single dose (concomitant treatment) groups with pyr. Taken orally at a dose of 20, 40 and 120 mg/kg and folinic taken I.M. at a dose of 0.1 mg/kg.</i>	7-5	87

No	Table	Chapter	Page
21.	<i>Statistical analysis (X^2) for chromosomal abnormalities in pyrimethamine-folinic concomitant treatment (pyr.+ fol. Concomit. treatment) groups and their negative control at the 3rd day post-treatment after a single dose.</i>	7-19	139
22.	<i>Statistical analysis (X^2) for chromosomal abnormalities in pyrimethamine-folinic concomitant treatment (pyr. +fol. Concomit. treatment) groups and their negative control at the 12th day post-treatment after a single dose</i>	7-20	142
23.	<i>Statistical analysis (X^2) for chromosomal abnormalities detected in pyrimethamine-folinic concomitant treatment groups (pyr. + fol. Concomit. treatment) as a comparison between results of the 3rd and 12th day post-treatment after a single dose</i>	7-21	145
24.	<i>Statistical analysis (X^2) for chromosomal abnormalities for the single dose groups and their negative control groups at the third day post-treatment.</i>	7-22	148
25.	<i>Statistical analysis (X^2) for chromosomal abnormalities for the single dose groups and their negative control groups at the 12th day post-treatment.</i>	7-23	153
26.	<i>Statistical analysis (X^2) for chromosomal abnormalities in repeated dose groups [pyrimethamine (pyr.); pyrimethamine + folinic pretreatment (pyr. + fol prettt) and pyrimethamine + folinic concomitant treatment (pyr. + fol. Concomit. tt)] daily for one month</i>	7-24	158
27.	<i>Statistical analysis (X^2) for chromosomal abnormalities in positive control groups and their negative control at different interval of time.</i>	7-25	161